Vanderbilt researchers suggest that to reduce treatment-related regret for men with localized prostate cancer, treatment preparation should focus on shared decision-making and aligning patient expectations with treatment toxicity.

In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11 with moderate-to-severe asthma, offering a new option to these patients.

“Troy is a true professional, and his consistent actions and behavior not only make him a front-line hero, but a shining example of our Credo behaviors.”

A metatranscriptomics method developed by Vanderbilt researchers simultaneously characterizes viruses, microbiome and host response in nasal swabs, opening opportunities to explore molecular interactions directly in clinical samples.

A novel CRISPR screen developed by Vanderbilt researchers identified a promising new target for anti-inflammatory therapeutics.

New research from Vanderbilt could aid efforts to promote kidney regeneration after injury or to develop engineered organs.